PMID- 34524004
OWN - NLM
STAT- MEDLINE
DCOM- 20220516
LR  - 20220531
IS  - 1557-8852 (Electronic)
IS  - 1084-9785 (Linking)
VI  - 37
IP  - 4
DP  - 2022 May
TI  - Apatinib Combined with Paclitaxel and Cisplatin Neoadjuvant Chemotherapy for 
      Locally Advanced Esophageal Squamous Cell Carcinoma.
PG  - 324-331
LID - 10.1089/cbr.2021.0086 [doi]
AB  - Background: We conducted a trial to evaluate the efficacy and safety of apatinib, 
      a tyrosine inhibitor against vascular endothelial growth factor receptor 2, 
      combined with neoadjuvant chemotherapy in patients with locally advanced 
      esophageal squamous cell carcinoma (ESCC). Materials and Methods: One hundred 
      twenty six patients were randomized into two cycles of paclitaxel and cisplatin 
      (TP) (n = 61) or combined with apatinib (Apa+TP) (n = 65), followed by surgery. 
      The primary endpoint was objective response rate (ORR). Secondary endpoints 
      included pathological complete response (pCR), safety, R0 resection rate, and 
      operative complication rates. Results: Compared with TP chemotherapy alone, 
      adding apatinib to neoadjuvant treatment significantly increased ORR (Apa+TP: 
      80.0% vs. TP: 54.1%, respectively; p = 0.004). Apa+TP achieved higher pCR rate 
      compared with TP alone (15.4% vs. 4.92%, respectively; p = 0.101). Similar 
      incidences of toxic effects were found between those two groups. No grade 3 or 4 
      adverse events (AEs) were observed. Meanwhile, apatinib-related AEs, including 
      hypertension, proteinuria, and hand-and-foot syndrome, were mild. The R0 
      resection rate was 100% in both groups. No significant differences in operation 
      time, intraoperative bleeding, and postoperative complications were observed, and 
      no serious complications occurred. Conclusions: Adding apatinib to TP neoadjuvant 
      chemotherapy significantly increased ORR, suggesting an advantage of 
      anti-angiogenesis in ESCC. Clinical Trials.gov ID: ChiCTR-TRC-1800017662.
FAU - Zhao, Jidong
AU  - Zhao J
AD  - Department of Thoracic Surgery, Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, China.
FAU - He, Ming
AU  - He M
AD  - Department of Thoracic Surgery, Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, China.
FAU - Li, Jie
AU  - Li J
AD  - Department of Medical Affairs, Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, China.
FAU - Li, Dan
AU  - Li D
AD  - Department of Thoracic Surgery, Hospital of Jingxing County, Jingxing, China.
FAU - Zhao, Yang
AU  - Zhao Y
AD  - Office of Academic Research, Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, China.
FAU - Li, Xinhui
AU  - Li X
AD  - Cancer Institute, Fourth Hospital of Hebei Medical University, Shijiazhuang, 
      China.
FAU - Zhang, Xiangmei
AU  - Zhang X
AD  - Research Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, 
      China.
FAU - Chen, Xin
AU  - Chen X
AD  - Department of Thoracic Surgery, Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, China.
FAU - Liu, Yunjiang
AU  - Liu Y
AUID- ORCID: 0000-0001-7202-2004
AD  - Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
FAU - Zhao, Liyan
AU  - Zhao L
AD  - Department of Internal Medicine, First Hospital of Xingtai City, Xingtai, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20210915
PL  - United States
TA  - Cancer Biother Radiopharm
JT  - Cancer biotherapy & radiopharmaceuticals
JID - 9605408
RN  - 0 (Pyridines)
RN  - 5S371K6132 (apatinib)
RN  - P88XT4IS4D (Paclitaxel)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Cisplatin/therapeutic use
MH  - *Esophageal Neoplasms/drug therapy/pathology
MH  - *Esophageal Squamous Cell Carcinoma/drug therapy/pathology
MH  - Humans
MH  - Neoadjuvant Therapy
MH  - Paclitaxel/therapeutic use
MH  - *Pyridines/therapeutic use
OTO - NOTNLM
OT  - apatinib
OT  - cisplatin
OT  - esophageal squamous cell carcinoma
OT  - neoadjuvant chemotherapy
OT  - paclitaxel
EDAT- 2021/09/16 06:00
MHDA- 2022/05/17 06:00
CRDT- 2021/09/15 12:21
PHST- 2021/09/16 06:00 [pubmed]
PHST- 2022/05/17 06:00 [medline]
PHST- 2021/09/15 12:21 [entrez]
AID - 10.1089/cbr.2021.0086 [doi]
PST - ppublish
SO  - Cancer Biother Radiopharm. 2022 May;37(4):324-331. doi: 10.1089/cbr.2021.0086. 
      Epub 2021 Sep 15.